ALZM weekend review

PennyTipster.com

Dear Valued Subscriber,

ALZM came hot out of the gates on Friday morning. After about 30 minutes of trading we saw the following 

In our opinion, Friday was blatant shorting and serious manipulation by a handful of market makers. Market makers are not legally allowed to work in concert with each other, however after watching Friday's trading it seems clear to many that this is exactly what we've been seeing.

Remember, Organ Transport has been in existence for nearly 12 years, has had more than $10 million invested in it over the years in the research and development of the LifeCradle®. This is not some fly by night company!

Take a look at this week's RegSho List posted by FINRA with regards to ALZM's short volume. 

Monday – 2,360,381
Tuesday – 2,870,790
Wednesday – 1,961,310
Thursday – 3,869,136
Friday – 3,740,478

What does this tell you? To us, it couldn't be more crystal clear. This number represents intra-day shorts as well as current short positions. The number as the week went on should have gone down and we saw just the opposite.

Even with all of that effort on their part, we believe they failed at their ultimate goal which in our opinion was to push the stock down so much that investors would all jump ship in fear. At the end of the day ALZM was only down 5% from Thursday's close and now these short sellers could be starting to get nervous.

We've always told our subscribers that the micro-cap market is extremely volatile and unfortunately trading desks with deep pockets can try and break the will of the everyday investor through scare tactics like intense shorting. 

ALZM is currently trading at $2.00 per share with some of the strongest volume that we have seen on a micro-cap stock in this price range. We believe short sellers may have overstepped their bounds in this particular situation. That could spell a significant short cover in the days ahead if investors hold strong and don't give in to their scare tactics!

On Thursday night ALZM released news indicating that they condemned the promotional activities on their stock due to inaccuracies. Our team only releases information that we can obtain through public filings, company press releases, corporate websites and obviously industry news. We have seen many people posting inaccurate information, but we are here to keep it real. 

In our opinion, the real story behind ALZM is so fascinating that we don't understand why some feel the need to release any inaccurate information. 

Here are our Top 10 reasons why we believe short sellers may have underestimated ALZM as a company:

1. Organ Transport has been in existence for nearly 12 years, has had more than $10 millioninvested in it over the years in the research and development of the LifeCradle®.

2. ALZM has collaborated with OPOs, surgeons and research scientists from major academic medical centers and institutes across the nation, as well as in Australia and Europe.

3. The US medical supply industry is HOT, with annual revenues of around $75 Billion and it's not going anywhere!

4. Johnson & Johnson sees annual revenues of $17.7 Billion in their medical device and supply market alone!

5. According to phcconsulting.com, the core product categories are historically recession-resistant and will continue to grow regardless of still-restrictive credit market conditions that may ultimately affect spending decisions at the hospital customer base.
6. More than 100,000 men, women and children currently need life-saving organ transplants and every 10 minutes another name is added to the national organ transplant waiting list.

7. Only 27% of donated hearts and only 9% of donated lungs actually can be transplanted currently.

8. Because their product extends the life of these organs, ALZM could be in a position to literally save the lives of millions of people!

9. A key addition to the company occurred in 2006 when past U.S. Dept. of Health and Human Services Secretary Tommy Thompson, a strong advocate for organ donation and transplantation, joined the Board of Directors of Organ Transplant Systems, Inc.

10. PerkinElmer, Inc. (PKI), an industry peer, was trading around $13 in mid-2009 and recently has traded over $28!

We are continuing our Strong Announcement on ALZM and we encourage our subscribers to keep it on their radar!

Sincerely,
PennyTipster.com